Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Disposition of Common Shares of Small Pharma Inc.

Disposition of Common Shares of Small Pharma Inc.

  • Post published:October 3, 2023
  • Post category:Press Release
Read more about the article Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

  • Post published:September 26, 2023
  • Post category:Press Release
Read more about the article Cybin Set to Acquire British DMT Drug Developer Small Pharma

Cybin Set to Acquire British DMT Drug Developer Small Pharma

  • Post published:August 28, 2023
  • Post category:News
Read more about the article Small Pharma Reports Fiscal First Quarter 2024 Highlights

Small Pharma Reports Fiscal First Quarter 2024 Highlights

  • Post published:July 28, 2023
  • Post category:Press Release
Read more about the article Small Pharma Announces SPL028 R&D Strategy Update

Small Pharma Announces SPL028 R&D Strategy Update

  • Post published:July 5, 2023
  • Post category:Press Release
Read more about the article Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023  and Recent Business Highlights

Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights

  • Post published:June 28, 2023
  • Post category:Press Release
Read more about the article Small Pharma Announces Significant Developments In Intellectual Property Portfolio

Small Pharma Announces Significant Developments In Intellectual Property Portfolio

  • Post published:May 25, 2023
  • Post category:Press Release
Read more about the article Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

  • Post published:May 3, 2023
  • Post category:Press Release
Read more about the article Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026

Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026

  • Post published:April 4, 2023
  • Post category:Press Release
Read more about the article Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry

Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry

  • Post published:March 7, 2023
  • Post category:Press Release

End of content

No more pages to load

Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More